Bevacizumab administered intraperitoneally as palliative treatment of malignant refractory ascites.
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2015
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Malignant ascites
- Focus Therapeutic Use
- 01 Sep 2015 Assumed phase chosen as II rather than IV as bevacizumab was not approved for peritoneal cancer indication in EU until Aug 2014. Formulation is perfusion, but this is not listed in available formulations for CT.
- 01 Sep 2015 New trial record